Author Affiliation: Neuroepidemiology Section, Laboratory for Epidemiology, Demography, Biometry, National Institute on Aging, Bethesda, Md.
In this issue of THE JOURNAL, Aisen and colleagues1 from
the Alzheimer's Disease Cooperative Study (ADCS) report the results of a 1-year
double-blind, placebo-controlled randomized trial designed to test whether
2 nonsteroidal anti-inflammatory drugs (NSAIDs), naproxen and rofecoxib, slowed
cognitive decline in patients with mild to moderate Alzheimer disease (AD).
These NSAIDs were tested separately against their own placebo, and the authors
used several analytical strategies to test for an effect. The primary outcome
measure (Alzheimer Disease Assessment Scale-cognitive subscale [ADAS-Cog]
score, which measures the cognitive domains impaired in AD) showed no difference
between the placebo and treatment groups with either of the NSAIDs. Similarly,
the secondary outcomes (measures of activities of daily living, quality of
life, and time to institutionalization or death) showed no evidence of a treatment
Launer LJ. Nonsteroidal Anti-inflammatory Drugs and Alzheimer DiseaseWhat's Next?. JAMA. 2003;289(21):2865-2867. doi:10.1001/jama.289.21.2865